These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23922904)

  • 1. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes.
    Podewils LJ; Gler MT; Quelapio MI; Chen MP
    PLoS One; 2013; 8(7):e70064. PubMed ID: 23922904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopia.
    Tola HH; Holakouie-Naieni K; Mansournia MA; Yaseri M; Tesfaye E; Mahamed Z; Sisay MM
    Sci Rep; 2019 Dec; 9(1):20030. PubMed ID: 31882784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia.
    Bastard M; Sanchez-Padilla E; Hewison C; Hayrapetyan A; Khurkhumal S; Varaine F; Bonnet M
    J Infect Dis; 2015 May; 211(10):1607-15. PubMed ID: 25312040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.
    Javaid A; Ullah I; Masud H; Basit A; Ahmad W; Butt ZA; Qasim M
    Clin Microbiol Infect; 2018 Jun; 24(6):612-617. PubMed ID: 28970158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment.
    Franke MF; Appleton SC; Bayona J; Arteaga F; Palacios E; Llaro K; Shin SS; Becerra MC; Murray MB; Mitnick CD
    Clin Infect Dis; 2008 Jun; 46(12):1844-51. PubMed ID: 18462099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China.
    Wei XL; Yin J; Zou GY; Zhang ZT; Walley J; Harwell J; Li HT; Sun Q; Li RZ; Wang LX; Zhang XL
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):413-9. PubMed ID: 25859996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
    BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly successful treatment outcome of multidrug-resistant and genetic diversity of multidrug-resistant Mycobacterium tuberculosis strains in Rwanda.
    Muvunyi CM; Ngabonziza JCS; Uwimana I; Harelimana JD; Mucyo Y; Sebatunzi OR; Muvunyi TZ; Seruyange E; Masaisa F; Mazarati JB; Gasana M
    Trop Med Int Health; 2019 Jul; 24(7):879-887. PubMed ID: 31066112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.
    Alene KA; Viney K; McBryde ES; Tsegaye AT; Clements AC
    Trop Med Int Health; 2017 Mar; 22(3):351-362. PubMed ID: 27978594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
    Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.
    Satti H; McLaughlin MM; Hedt-Gauthier B; Atwood SS; Omotayo DB; Ntlamelle L; Seung KJ
    PLoS One; 2012; 7(10):e46943. PubMed ID: 23115633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
    J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India.
    Isaakidis P; Cox HS; Varghese B; Montaldo C; Da Silva E; Mansoor H; Ladomirska J; Sotgiu G; Migliori GB; Pontali E; Saranchuk P; Rodrigues C; Reid T
    PLoS One; 2011; 6(12):e28066. PubMed ID: 22145022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
    Kibret KT; Moges Y; Memiah P; Biadgilign S
    Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis.
    Tobón Á; Rueda J; Cáceres DH; Mejía GI; Zapata EM; Montes F; Ospina A; Fadul S; Paniagua L; Robledo J
    Biomedica; 2020 Dec; 40(4):616-625. PubMed ID: 33275341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006.
    Malla P; Kanitz EE; Akhtar M; Falzon D; Feldmann K; Gunneberg C; Jha SS; Maharjan B; Prasai MK; Shrestha B; Verma SC; Zignol M
    PLoS One; 2009 Dec; 4(12):e8313. PubMed ID: 20041140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.